Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rasburicase

Drug Profile

Rasburicase

Alternative Names: Elitek; Fasturtec; Rasuritek; Recombinant urate oxidase - Sanofi-Aventis; SR 29142; Uricase - Sanofi-Aventis

Latest Information Update: 15 Jul 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator sanofi-aventis
  • Developer Sanofi
  • Class Antigouts; Oxidoreductases
  • Mechanism of Action Urate oxidase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hyperuricaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hyperuricaemia

Most Recent Events

  • 14 Jul 2017 No recent reports on development identified - Registered for Hyperuricaemia (Chemotherapy-induced) in Iceland and Liechtenstein (IV,infusion)
  • 15 Mar 2016 Biomarkers information updated
  • 06 Aug 2014 Rasburicase licensed to Emcure Pharmaceuticals in India
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top